Research progress on Copeptin as a biomarker of metabolic diseases

Zhu Jie

您当前的位置：

首页 >

文章列表页 >

Research progress on Copeptin as a biomarker of metabolic diseases

更新时间：2023-04-16

- Research progress on Copeptin as a biomarker of metabolic diseases
- Journal of Chongqing Medical University Vol. 48, Issue 1, Pages: 76-80(2023)
- 作者机构：
  
  重庆医科大学附属第二医院内分泌代谢科,重庆,400010
- 作者简介：
- 基金信息：
- DOI：
  CLC： R589
- Revised：2022-04-31，
  
  Accepted：06 May 2022，
  
  Published：2023
- 稿件说明：
移动端阅览
Zhu Jie. Research progress on Copeptin as a biomarker of metabolic diseases[J]. Journal of chongqing medical university, 2023, 48(1): 76-80.
DOI：

Zhu Jie. Research progress on Copeptin as a biomarker of metabolic diseases[J]. Journal of chongqing medical university, 2023, 48(1): 76-80. DOI：

摘要

精氨酸加压素是一种由下丘脑合成以应对血浆渗透压增加和血容量减少的激素，它可以与精氨酸加压素受体结合影响糖脂代谢。最近有研究表明，Copeptin是一个稳定、敏感且暂未发现有生物活性的精氨酸加压素替代标志物，与精氨酸加压素以等摩尔量释放入血，其循环水平升高与糖尿病、糖尿病并发症、肥胖、胰岛素抵抗、高血压、高脂血症、非酒精性脂肪性肝病等代谢性疾病密切相关。积极探索Copeptin与代谢性疾病中的关系有助于疾病的早期诊断。

Abstract

Arginine vasopressin (AVP) is a hormone synthesized from the hypothalamus in response to increased plasma osmotic pressure and decreased blood volume

which influences glucolipid metabolism by binding to AVP receptors. Recent studies show that Copeptin

co-secreted with AVP in equimolar amounts

is considered stabilized

sensitive and not bioactive surrogate marker of AVP. Elevated plasma levels of Copeptin are essentially associated with diabetes

diabetic complications

obesity

insulin resistance

hyper-tension

hyperlipidemia

non-alcoholic fatty liver disease and other metabolic diseases. Therefore

exploring the relationship between Copeptin and metabolic diseases actively will contribute to the early diagnosis of related diseases.

关键词

Keywords

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment and evaluation of a new method for studying fatty acid uptake in vivo

Research progress of caloric restriction in the prevention and treatment of obesity related metabolic diseases based on gut microbiota

Research progress on the effect of fetuin B on glucolipid metabolism

Related Author

Liu Jun

Zuo Guoqing

Ruan Xiongzhong

Chen Yaxi

Yang Ping

Ye Jiamei

Zhang Rui

Related Institution

Chongqing Key Laboratory of Lipid and Glucose Metabolism,Chongqing Medical University

Department of Gastroenterology,Chongqing Hospital of Traditional Chinese Medicine

School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine

Department of Endocrinology and Metabolism, Second Affiliated Hospital of Chongqing Medical University

⁰